AU2007232279B2 - Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide - Google Patents

Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide Download PDF

Info

Publication number
AU2007232279B2
AU2007232279B2 AU2007232279A AU2007232279A AU2007232279B2 AU 2007232279 B2 AU2007232279 B2 AU 2007232279B2 AU 2007232279 A AU2007232279 A AU 2007232279A AU 2007232279 A AU2007232279 A AU 2007232279A AU 2007232279 B2 AU2007232279 B2 AU 2007232279B2
Authority
AU
Australia
Prior art keywords
cancer
dose
compound
administered
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007232279A
Other languages
English (en)
Other versions
AU2007232279A1 (en
Inventor
Kenna Lynn Anderes
Alessandra Blasina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2007232279A1 publication Critical patent/AU2007232279A1/en
Application granted granted Critical
Publication of AU2007232279B2 publication Critical patent/AU2007232279B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007232279A 2006-04-04 2007-03-26 Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide Ceased AU2007232279B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78927606P 2006-04-04 2006-04-04
US60/789,276 2006-04-04
PCT/IB2007/000928 WO2007113671A1 (en) 2006-04-04 2007-03-26 Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide

Publications (2)

Publication Number Publication Date
AU2007232279A1 AU2007232279A1 (en) 2007-10-11
AU2007232279B2 true AU2007232279B2 (en) 2010-05-06

Family

ID=38421777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007232279A Ceased AU2007232279B2 (en) 2006-04-04 2007-03-26 Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide

Country Status (14)

Country Link
US (1) US20090312280A1 (enExample)
EP (1) EP2007375A1 (enExample)
JP (1) JP2007277240A (enExample)
KR (1) KR20080100838A (enExample)
CN (1) CN101415417A (enExample)
AR (1) AR060284A1 (enExample)
AU (1) AU2007232279B2 (enExample)
BR (1) BRPI0709731A2 (enExample)
CA (1) CA2648371A1 (enExample)
IL (1) IL194340A0 (enExample)
MX (1) MX2008012791A (enExample)
RU (1) RU2409361C2 (enExample)
TW (1) TW200806301A (enExample)
WO (1) WO2007113671A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009113436A1 (ja) * 2008-03-14 2011-07-21 国立大学法人 千葉大学 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法
EP2258378A4 (en) * 2008-03-27 2012-01-04 Taiho Pharmaceutical Co Ltd ANTICROBIAL AGENTS WITH A CYTIDINE DERIVATIVE AND CARBOPLATIN
KR101676062B1 (ko) * 2009-04-11 2016-11-14 어레이 바이오파마 인크. Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
KR101716012B1 (ko) 2011-12-31 2017-03-13 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론
KR101684039B1 (ko) 2011-12-31 2016-12-07 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075499A1 (en) * 2003-01-09 2005-04-07 Agouron Pharmaceuticals, Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075499A1 (en) * 2003-01-09 2005-04-07 Agouron Pharmaceuticals, Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Also Published As

Publication number Publication date
US20090312280A1 (en) 2009-12-17
AU2007232279A1 (en) 2007-10-11
RU2008139406A (ru) 2010-04-10
JP2007277240A (ja) 2007-10-25
RU2409361C2 (ru) 2011-01-20
TW200806301A (en) 2008-02-01
IL194340A0 (en) 2009-08-03
WO2007113671A1 (en) 2007-10-11
BRPI0709731A2 (pt) 2011-07-26
CN101415417A (zh) 2009-04-22
CA2648371A1 (en) 2007-10-11
KR20080100838A (ko) 2008-11-19
AR060284A1 (es) 2008-06-04
MX2008012791A (es) 2008-10-15
EP2007375A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
US20090312280A1 (en) Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
MX2007003314A (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
US20050272755A1 (en) Method for treating abnormal cell growth
AU2008282331A1 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (CD49E)
CN105560239B (zh) Cx4945作为制备胃癌顺铂耐药放射耐受逆转作用药物的应用
CN101384264B (zh) 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
HK1131034A (en) Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
US20110236506A1 (en) Pharmaceutical association containing lipoic acid and hydroxycitric acid as active ingredients
US10494412B2 (en) Peptides
WO2015187853A2 (en) F10 inhibits growth of pc3 xenografts and enhances the effects of radiation therapy
AU2011253816A1 (en) Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
CN101193644A (zh) 使用蒽醌类治疗过度增殖性疾病
HK1127956A (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
HK40118239A (en) Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract, a scutellaria baicalensis georgi (s) extract or a compound from such extracts
CN120349384A (zh) 一种能引起肿瘤细胞免疫原性死亡的多肽及其制备方法、给药系统和应用
CN102448454B (zh) 包含plk1抑制剂和抗肿瘤剂的治疗性组合
WO2010081778A1 (en) Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
CN102448454A (zh) 包含plk1抑制剂和抗肿瘤剂的治疗性组合

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMBINATION THERAPY OF (2R)-2-AMINO-2-CYCLOHEXYL-N-(2-(1-METHYL-1H-PYRAZOL-4-YL)-6-OXO-5,6-DI HYDRO-1H-[1,2]DIAZEPINO[4,5,6-CD]INDOL-8-YL)ACETAMIDE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired